FUJIFILM Holdings Corp · TSE:4901
FUJIFILM — Merger or Acquisition (February 2008)
8 slides from FUJIFILM's merger presentation, Feb 26, 2008
Slide 1: Strategic Capital and Business Alliance Between Fujifilm, Taisho Pharmaceutical and Toyama Chemical
Strategic Capital and Business Alliance Between Fujifilm, Taisho Pharmaceutical and Toyama Chemical February 26, 2008 FORWARD-LOOKING FORWARD-LOOKING STATEMENTS STATEMENTS Forward-looking Forward-looking statements statements such such as as those those relating relating toto earnings earnings forec
Slide 2: Middle and Long Term Management Strategies
Middle and Long Term Management Strategies Future Business Portfolio that accelerates Fujifilm’s Growth Healthcare Medical Systems Life Sciences The FUJIFILM Group's Broad Range of Technologies and Know-how Chemical materials library Highly advanced Image processing manufacturing technologies techno
Slide 3: Expanding Business Domain
Expanding Business Domain Healthcare Medical systems Life sciences Prevention Diagnosis Treatment X-ray imaging (FCR / film) Endoscopes Radiopharmaceuticals Internal care FUJIFILM RI Pharma products (October 2006-) Business Business expansion expansion Medical Functional Blood analysis Radio diagnos
Slide 4: Significance of the Strategic Partnership
Significance of the Strategic Partnership Toyama Chemical A leading, world-class drug discovery company Pursuing the drug discovery mechanism Innovative, superior R&D capabilities Strong pipeline based on a new action mechanism Pharmaceuticals for treating influenza, Alzheimer’s disease, and other d
Slide 5: Toyama Chemical as a Strategic Partner
Toyama Chemical as a Strategic Partner • An R&D-oriented innovative drug developer / manufacturer Technological • Aggressive stance in incorporating synergies cross-industrial technologies Toyama Fujifilm Chemical High Corporate culture that growth potential generates synergies with Fujifilm • Pipel
Slide 6: Future vision for the Medical Systems/Life Sciences Business
Future vision for the Medical Systems/Life Sciences Business Toyama Chemical’s technology (Pharmaceutical developer) Treatment Diagnosis Unique innovative drugs Collaboration in the field of self-medication Prevention Taisho Pharmaceutical’s development/ marketing capacity “Comprehensive healthcare
Slide 7: (Appendix) Scheme of the Capital Alliance
(Appendix) Scheme of the Capital Alliance Toyama Chemical allocated new shares Amount of cash invested through a third party allocation in the Alliance: ¥130 billion (Planned) (at the end of February 2008) Companies underwriting the allocation and amounts: Accept TOB Expenses for R&D and capital exp
Slide 8: Corporate philosophy
We will use leading-edge, proprietary technologies to provide top-quality products and services that contribute to the advancement of culture, science, technology and industry, as well as improved health and environmental protection in society. Our overarching aim is to help enhance the quality of l
Fujifilm Holdings — Merger or Acquisition (February 2008) on 6ix